NWBO has NO manufacturing facilities in the US. They will NEVER have any manufacturing facilities in the US. They will sign an agreement with a company when time comes to produce their vaccines.
I am assuming that what you are set on means they are funding CRL's expansion is this sentence: "Additional substantial costs relate to the maintenance and substantial expansion of manufacturing capacity, in both the U.S. and Europe."
I am astounded that this in your mind means that we are funding CRL's expansion. It could be referring to the development, implementation and approval of Flaskworks, which can be done in corporation with any University or research facility. In addition, it could refer to payments to UCLA or other research facilities to get new trials going.
As they do not have any agreement with CRL at this time, funding their build out is likely the least reasonable option
Market Data 
Markets 
AI
